Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews

Volumn 9, Issue , 2017, Pages 29-35

  Abdalla, Abuelmagd ^a   Byrne, Niamh ^a   Conway, Richard ^a   Walsh, Thomas ^a   Mannion, Geraldine ^a   Hanly, Michael ^a   O’Sullivan, Miriam ^a   Curran, Ann Maria ^a   Carey, John J ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Adult; Biologic therapy; Biosimilar exchange; Infliximab; Rheumatic diseases

Indexed keywords

BIOSIMILAR AGENT; C REACTIVE PROTEIN; INFLIXIMAB; INFLIXIMAB DYYB;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHMA; CELLULITIS; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EAR INFECTION; EYE INFECTION; FEMALE; FOLLOW UP; GASTROENTERITIS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION RISK; LOADING DRUG DOSE; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; NAUSEA; NON SMALL CELL LUNG CANCER; PAIN ASSESSMENT; PATIENT ASSESSMENT; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 85016146498     PISSN: None     EISSN: 1179156X     Source Type: Journal    
DOI: 10.2147/OARRR.S124975     Document Type: Article

References (17)

1. WebMed [homepage on the Internet]. Biologics for Rheumatoid Arthritis Treatment-Enbrel, Humira, Remicade, and More. Available from: http://www.webmd.com/rheumatoid-arthritis/guide/biologics.
2. ResearchandMarkets. Competitor Analysis: TNF Antibodies 2015-Biosimilars and Biosuperiors of Humira, Remicade and Enbrel. Available from: http://www.researchandmarkets.com/research/xr7tsg/ competitor.
3. European Medicines Agency. Q&A: Similar biological products-Biosimilar medicines. Available from: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/special_topics/document_listing/document_listing_ 000318.jsp.
4. Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S102-S106.
5. Baji P, Péntek M, Czirják L, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ. 2014;15(Suppl 1):S53-S64.
6. McCarthy G, Ebel Bitoun C, Guy H. Introduction of an Infliximab Biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health. 2013;16(7):A558.
7. Whitehouse J, Walsh K, Papandrikopoulou A, Hoad R. The cost saving potential of utilizing biosimilar medicines in biologic naive severe rheumatoid arthritis patients. Value Health. 2013;16(7):A573.
8. Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014; 15(S1):65-71.
9. Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742-756.
10. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355-363.
11. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346-354.
12. Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677-1683.
13. Glintborg B, Kringelbach T, Sørensen IJ, et al. Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis-impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and Danbio Registry. Presented at: 17th Annual European Congress of Rheumatology; June 8-1,1 2016; London, UK. eular abstract archive.
14. Rubio E, Ruiz A, Lόpez J, et al. Prospective study of 78 patients treated with infliximab biosimilar Remsima®. Ann Rheum Dis. 2016;75:1006.
15. Batticciotto A, Parisi S, Li Gobbi GF, et al. Safety and efficacy of switching from innovator to biosimilar infliximab in patients affected by spondyloarthritis. A 6-month observational study. Ann Rheum Dis. 2016;75(Suppl 2):1-806.
16. Sheppard M, Hadavi S, Hayes F, Kent J, Dasgupta B. Preliminary data on the introduction of the infliximab biosimilaR (CT-P13) to a real world cohort of rheumatology patients. Ann Rheum Dis. 2016;75:1011.
17. Goll GL, Olsen IG, Jorgensen KK, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway. Presented at: ACR 2016 Annual Meeting; 2016. Abstract 19L. Available from: http://acrabstracts.org/abstract/ biosimilar-infliximab-ct-p13-is-not-inferior-to-originator-infliximabresults-from-a-52-week-randomized-switch-trial-in-norway/